Connect with us
Grifols and PharmaMar significantly dropped Spanish pharmaceutical stocks, with declines of 49.1% and 22.5% respectively in the first half of 2024. Although other companies like Rovi...
Grifols rose almost 3% on the stock market at the start of the trading day this Friday, after the Catalan firm assured that it will be...
Grifols increased its private bond issue by €300 million, totaling €1.3 billion. The bonds, maturing in May 2030 with a 7.5% annual coupon, will repay part...
Goldman Sachs increased its stake in Grifols from 5.8% to 6.4%, amid a bearish attack by Gotham City Research, coinciding with Grifols' Q1 results. Melqart reduced...
Berenberg has slashed Grifols' target price by 23% to 19.8 euros due to higher-than-expected net debt. Despite this, Berenberg remains optimistic about Grifols' potential, estimating a...
Grifols reports positive results from its Phase IV study of Fanhdi for von Willebrand disease (VWD) treatment, showing safety and efficacy. Presented at the 2024 World...
Grifols leads the IBEX 35's mid-morning gains, rising 3.42% to 9.02 euros, marking its fourth consecutive positive day. Despite falling over 40% for the year, the...
The Spanish pharma sector faced a downturn in the stock market in Q1 of 2024, with a collective market capitalization drop of 15.8% for six listed...
Europacific Growth Fund, legal owner of Grifols shares, lent over 100 million euros worth of shares, reducing its ownership from 3.4% to 3.2%. Capital Research and...
BlackRock, Capital Research and Management Company, and Jefferies Financial Group lend over 170 million euros in Grifols shares. Specifically, BlackRock, which has a 4.3% stake in...